Imatinib Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Imatinib market is segmented by Drug Formulation (Capsules, Tablets ), Application, and Geography.

Imatinib Drug Market Snapshot

Imatinib drug market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Imatinib Drug Market is expected to register a CAGR of 3% during the forecast period. Several factors are propelling the growth of this market such as increasing prevalence of cancer, increase in demand of target drug therapy and patient expiry of imatinib drug. For instance, according to National Cancer Institute in 2017 the number of new cases for leukemia is 62,130 and number of deaths was 24,500 which shows increasing prevalence of cancer patients in future and propell the imatinib drug market. In addition, Food and Drug Administration (FDA) approves enasidenib (IDHIFA®) a target drug therapy for patients who has Acute myeloid leukemia (specifically genetic mutation IDH2). Moreover, Imatinib drug is helpful in treating the patient with cancer by blocking the growth of eosinophils. This drug has been attributed to its higher efficacy in treating the Chronic Eosinophilic Leukemia, Hyper-Eosinophilic Syndrome, Gastrointestinal Stromal Tumors (GIST) and many more, However, high cost of imatinib with several substitute such as tarceva, sprycel and tasigna may hamper the market to certain extent.

Scope of the Report

As per scope, imatinib drug comes under world health organization’s list of essential drugs used to treat cancers such as chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). An imatinib, tyrosine kinase inhibitor is a chemotherapy drug which acts by reducing or preventing the progression of cancer cells. Imatinib Drug Market is segmented by drug formulation, Application Type and Geography.

By Drug Formulation
By Application Type
Philadelphia Positive Chronic Myeloid Leukemia
Hyper-Eosinophilic Syndrome (HES)
Myelodysplastic Syndrome (MDS)
Myeloproliferative Diseases (MPD)
Gastrointestinal Stromal Tumors (GIST)
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Application of Imatinib Drug in Chronic Eosinophilic Leukemia Segment is expected to Witness a Healthy Growth.

Chronic eosinophilic leukemia will show healthy growth in the future attributing to the increasing prevalence of cancers. Chronic eosinophilic leukemia (CEL) is a disorder in which eosinophil count is greater than 1500 µl in peripheral blood also called hyper-eosinophilia. It is a rare myeloproliferative neoplasm, overproduction of eosinophils in the bone marrow. This imatinib drug helps in treating the disorder by stopping the tyrosine kinase enzyme which blocks the abnormal eosinophils. Imatinib drug is more beneficial in patients who have leukemia from a genetic mutation. Moreover, Imatinib drug also helps in improving blood counts and symptoms very fast which makes this drug highly adopted by the targeted patient pool and promotes the revenue growth of the imatinib drug market.

Gastrointestinal Stromal Tumors (GIST) is also showing a significant share as this is a type of tumor that arises in the gastrointestinal tract (stomach and small intestine). Imatinib has been the first-line therapy for GIST. The drug targets KIT and PDGFRA (platelet-derived growth factor receptor A) proteins blocking the growth of tumor cells.

In addition, incidences of leukemia worldwide leading to high demand of imatinib drug to treat the disorder and promotes the growth of market

Imatinib Drug Market

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global Imatinib Drug Market due to increasing incidences of cancer and growing healthcare concern. As per the National Cancer Institute, in 2018 an estimate of 1.7 million new cases of cancer was diagnosed wherein these drugs were used and thus promoting the growth of the imatinib drug market. Moreover, R&D expenditure in healthcare (oncology) is also anticipated to propel the growth of the imatinib drug market in North America. Furthermore, increasing healthcare expenditure and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Imatinib Drug Market

Competitive Landscape

The Imatinib Drug Market is fragmented in terms of competition and consists of several major players. Some of the companies which are currently dominating the market are Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cipla Inc and Apotex Inc.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Prevalence of cancer

      2. 4.2.2 Increase in demand of target drug therapy

      3. 4.2.3 Patient expiry of Imatinib drug

    3. 4.3 Market Restraints

      1. 4.3.1 Presence of substitute drug

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Formulation

      1. 5.1.1 Capsules

      2. 5.1.2 Tablets

    2. 5.2 By Application Type

      1. 5.2.1 Philadelphia Positive Chronic Myeloid Leukemia

      2. 5.2.2 Hyper-Eosinophilic Syndrome (HES)

      3. 5.2.3 Myelodysplastic Syndrome (MDS)

      4. 5.2.4 Myeloproliferative Diseases (MPD)

      5. 5.2.5 Gastrointestinal Stromal Tumors (GIST)

      6. 5.2.6 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Sun Pharmaceutical Industries Ltd.

      2. 6.1.2 Novartis AG

      3. 6.1.3 Dr. Reddy’s Laboratories Ltd

      4. 6.1.4 Teva Pharmaceutical Industries Ltd.

      5. 6.1.5 Mylan N.V.

      6. 6.1.6 Cipla Inc

      7. 6.1.7 Apotex Inc

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Imatinib Drug Market market is studied from 2018 - 2026.

The Imatinib Drug Market is growing at a CAGR of 3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Sun Pharmaceutical Industries Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V, Dr. Reddy's Laboratories are the major companies operating in Imatinib Drug Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!